Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
   
Ask the Experts About

Hepatitis and HIV CoinfectionHepatitis and HIV Coinfection
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


what is the current tx for relapsing HepC
Dec 8, 2003

other than peg-intron, are there any other more recent treatments that offer higher sustainable remission rates for a person with Genotype 1A who quickly becomes negative following 3-6 mos of therapy; remains on therapy for total of 12 mos, with weight based dosing of peg intron, but relapses within 3-6 months of ending therapy? is a lower ongoing maintenance dosing appropriate to sustain remission after 12 mos of therapy?

Response from Dr. Dieterich

There are two brands of pegylated interferon, the peg intron that you mention and the pegasys brand. They are very similar. I usually switch brands when re treating. However our team usually treats the relapsers longer than 12 months often for 18 months. We think that will help prevent relapse. DTD



Previous
indirectly affected
Next
HIV & Liver Transplant

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement